Connect Biopharma FY2025 net loss $55.5M; cash runway extended by $20.2M placement

Connect Biopharma Holdings Ltd

2026-Q1 EPS reported -$0.34 vs consensus -$1.22 ▲ beat (+72.1%)

Net loss FY2025 $55.5M ($1.00 per share) vs $15.6M ($0.28 per share) in FY2024.
Cash and equivalents $44.3M at Dec 31, 2025; with private placement net proceeds, runway into H2 2027.
Private placement raised $20.2M gross from 6.13M shares at $3.25 each; closed March 31, 2026.
Phase 1 IV rademikibart showed rapid FEV1 improvement in asthma/COPD; Phase 2 Seabreeze STAT topline data expected mid-2026.
R&D expense increased to $37.8M (FY2025) from $29.3M due to Phase 2 study initiation.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.8

Connect Biopharma Holdings Ltd reported financial results for the three and twelve months ended December 31, 2025.

Period: the three and twelve months ended December 31, 2025
Result: reported results

Exact text from the filing

On March 31, 2026, Connect Biopharma Holdings Limited (the “Company”) issued a press release announcing its financial results for the fiscal year ended December 31, 2025.

View on SEC.gov

1349 earnings releases filed in the last 30 days. Browse all earnings releases →

Connect Biopharma Holdings Ltd filing history →

Source: SEC EDGAR

accession 0001835268-26-000012

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.